National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Blinatumomab (Blincyto®). HTA ID: 21031

Blinatumomab (Blincyto®) for the treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 05/07/2021
Rapid review completed 03/08/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.